Chiasma

About:

Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.

Website: https://chiasma.com

Twitter/X: chiasmapharma

Top Investors: ARCH Venture Partners, Sofinnova Investments, Rock Springs Capital, Abingworth, MPM Capital

Description:

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.